Tirzepatide: Published Research Summary

Introduction

Tirzepatide (LY3298176) has been the subject of an extensive body of peer-reviewed research encompassing preclinical pharmacology, phase 1 through phase 3 clinical trials, and post-approval investigations. This article provides a bibliographic summary of key published studies, with attribution and methodology context for each. It does not constitute a meta-analysis or draw independent conclusions; it reports what investigators reported in their publications.

Methodology Types in the Published Literature

Research on tirzepatide has employed several methodological approaches:

In vitro receptor pharmacology studies characterized tirzepatide's binding affinity, receptor selectivity, cAMP generation, and beta-arrestin recruitment in cell-based assay systems. These studies provided foundational data on the molecule's pharmacological profile at the molecular level.

Preclinical in vivo studies examined tirzepatide's pharmacokinetic properties and metabolic effects in rodent and non-human primate models. Findings from these models informed dose selection and the scientific rationale for clinical development; they are not directly extrapolatable to human populations and are reported here for methodological context.

Phase 1 clinical studies characterized the pharmacokinetics, pharmacodynamics, tolerability, and safety of tirzepatide in healthy human volunteers and small patient populations. Data from these studies informed dose selection for larger trials.

Phase 3 randomized controlled trials (RCTs) — the SURPASS and SURMOUNT programs — assessed tirzepatide's efficacy and safety against placebo and active comparators in large multicenter populations over 40- to 72-week treatment periods, generating the dataset reviewed by the FDA in its approval assessments.

Summary of Key Published Studies

Coskun et al., 2018 — Discovery and Early Clinical Characterization

Coskun and colleagues reported the discovery and initial characterization of LY3298176 (tirzepatide) in Molecular Metabolism in 2018 [1]. This paper described the molecule's design rationale, in vitro receptor pharmacology across GIP and GLP-1 receptor assays, preclinical in vivo metabolic data, and phase 1 clinical pharmacokinetic and pharmacodynamic data. The authors reported that co-stimulation of both incretin receptors in preclinical models was associated with effects on glucose regulation and body weight that differed from those of selective GLP-1 receptor agonists. Phase 1 clinical data indicated that tirzepatide reached steady-state concentrations consistent with extended-interval dosing and was associated with dose-dependent changes in pharmacodynamic markers of incretin receptor engagement.

Willard et al., 2020 — Molecular Pharmacology

Willard and colleagues published a detailed characterization of tirzepatide's molecular pharmacology in JCI Insight in 2020 [2]. In receptor-based assays, the authors reported that tirzepatide displayed full agonism at the GIPR and biased agonism at the GLP-1R, with preferential cAMP generation over beta-arrestin recruitment at the latter. The study further reported that beta-arrestin 1 limited GLP-1-stimulated but not tirzepatide-stimulated insulin secretion in isolated islet preparations, offering a proposed mechanistic distinction between tirzepatide and selective GLP-1R agonists that has informed subsequent pharmacological research. The full mechanistic context of these findings is covered in the tirzepatide mechanism of action article.

Sun et al., 2022 — Structural Biology

Sun and colleagues reported cryo-electron microscopy structures of tirzepatide in complex with both the GIPR and GLP-1R in the Proceedings of the National Academy of Sciences in 2022 [3]. The structural data identified the molecular contact points governing tirzepatide's engagement of each receptor and reported that tirzepatide adopted distinct binding poses at the two receptor complexes. The authors characterized specific residue interactions that explained the differential potency at each receptor subtype, providing an atomic-resolution foundation for mechanistic understanding of the dual agonist pharmacology.

Rosenstock et al., 2021 — SURPASS-1

Rosenstock and colleagues reported results from SURPASS-1 in The Lancet in 2021 [4]. SURPASS-1 was a 40-week, double-blind, randomized, placebo-controlled phase 3 trial conducted at 52 sites across India, Japan, Mexico, and the United States in 478 adults with type 2 diabetes managed by diet and exercise alone. The authors reported statistically significant reductions in HbA1c and body weight from baseline in all three tirzepatide dose groups relative to placebo at 40 weeks. The incidence of hypoglycemia was low across treatment groups, consistent with the glucose-dependent insulin secretory mechanism attributed to incretin receptor agonism.

Frías et al., 2021 — SURPASS-2

Frías and colleagues reported results from SURPASS-2 in the New England Journal of Medicine in 2021 [5]. SURPASS-2 was a 40-week, randomized, open-label, active-controlled phase 3 trial that enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide at three doses was compared with injectable semaglutide at its study-specified comparator dose. The authors reported that all three tirzepatide doses achieved greater mean reductions in HbA1c and body weight from baseline compared with semaglutide at 40 weeks, meeting prespecified noninferiority and superiority criteria. Gastrointestinal adverse events were reported in both treatment groups; nausea, diarrhea, and vomiting were among the most frequently reported events with tirzepatide.

Del Prato et al., 2021 — SURPASS-4

Del Prato and colleagues reported results from SURPASS-4 in The Lancet in 2021 [6]. SURPASS-4 was an open-label, randomized, active-controlled phase 3 trial enrolling 2,002 adults with type 2 diabetes and elevated cardiovascular risk. Tirzepatide was compared with titrated insulin glargine over a 52-week treatment period. The authors reported that tirzepatide at all doses produced greater reductions in HbA1c and body weight from baseline compared with insulin glargine, while the incidence of hypoglycemia was lower in the tirzepatide groups. Cardiovascular safety data from the trial were characterized as consistent with no increased risk relative to the comparator.

Jastreboff et al., 2022 — SURMOUNT-1

Jastreboff and colleagues reported results from SURMOUNT-1 in the New England Journal of Medicine in 2022 [7]. SURMOUNT-1 was a 72-week, double-blind, randomized, placebo-controlled phase 3 trial that enrolled 2,539 adults with obesity or with overweight and at least one weight-related comorbidity, excluding those with type 2 diabetes. The authors reported statistically significant mean reductions in body weight from baseline across all three tirzepatide dose groups compared with placebo at 72 weeks. Gastrointestinal adverse events were among the most frequently reported events. This study formed part of the regulatory submission supporting the FDA's November 2023 approval of tirzepatide for chronic weight management.

Garvey et al., 2023 — SURMOUNT-2

Garvey and colleagues reported results from SURMOUNT-2 in The Lancet in 2023 [8]. SURMOUNT-2 was a 72-week, double-blind, randomized, placebo-controlled phase 3 trial enrolling 938 adults with obesity or overweight who also had type 2 diabetes. The authors reported statistically significant mean reductions in body weight from baseline across tirzepatide dose groups compared with placebo, extending the findings from SURMOUNT-1 to participants with concurrent type 2 diabetes. The study contributed to the dataset reviewed by the FDA in its assessment of tirzepatide for chronic weight management.

Active Research Frontier

The tirzepatide literature remains an active and rapidly expanding area of investigation. Several research questions identified in the primary trial program are currently being addressed in registered and ongoing studies.

A dedicated cardiovascular outcomes trial (SURPASS-CVOT) was actively enrolling at the time this article was prepared, and cardiovascular endpoint data are anticipated to further characterize the long-term safety and outcomes profile. Pediatric data were generated in the SURPASS-PEDS trial, published in The Lancet in 2025, extending the investigational dataset to younger populations.

The mechanisms by which GIPR agonism contributes to observations in the SURPASS and SURMOUNT trials — including the role of GIP receptor signaling in adipose tissue and the central nervous system — represent an active area of basic pharmacology research. The durability of effects observed in 72-week trials, and the trajectory of outcomes over longer periods, are subjects of ongoing investigation. Investigational programs exploring tirzepatide in additional cardiometabolic conditions — including metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction — have reported early-phase data and remain active. Parallel clinical programs examining next-generation incretin compounds such as retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — represent a broader multireceptor research direction related to the same pharmacological family. Researchers can source analytically verified tirzepatide from SpartaLabs for non-clinical study.

References

1. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009

2. Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231. DOI: 10.1172/jci.insight.140532

3. Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119. PMID: 35333651. DOI: 10.1073/pnas.2116506119

4. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6

5. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. DOI: 10.1056/NEJMoa2107519

6. Del Prato S, Kahn SE, Pavo I, Wander PL, Chen Y, Landó LF, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. DOI: 10.1016/S0140-6736(21)02188-7

7. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. DOI: 10.1056/NEJMoa2206038

8. Garvey WT, Frías JP, Jastreboff AM, le Roux CW, Sattar N, Li T, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X